Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S Ward

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Life Sciences|January 1, 1997
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonistH E Shannon, D E Womer, F P Bymaster, et al.
Brain Research|June 12, 1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effectsF P Bymaster, P A Carter, S C Peters, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activityH E Shannon, M J Sheardown, F P Bymaster, et al.
Journal of Medicinal Chemistry|June 4, 1999
1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivativesL Jeppesen, P H Olesen, L Hansen, et al.
Journal of Medicinal Chemistry|February 14, 1997
Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndromeC H Mitch, T J Brown, F P Bymaster, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Life Sciences|January 1, 1997
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonistH E Shannon, D E Womer, F P Bymaster, et al.
Brain Research|June 12, 1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effectsF P Bymaster, P A Carter, S C Peters, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activityH E Shannon, M J Sheardown, F P Bymaster, et al.
Journal of Medicinal Chemistry|June 4, 1999
1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivativesL Jeppesen, P H Olesen, L Hansen, et al.
Journal of Medicinal Chemistry|February 14, 1997
Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndromeC H Mitch, T J Brown, F P Bymaster, et al.
Pageof 6